Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Non-Current Assets (2020 - 2026)

Cytek Biosciences filings provide 6 years of Other Non-Current Assets readings, the most recent being $6.7 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 40.87% to $6.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.7 million, a 40.87% increase, with the full-year FY2025 number at $6.7 million, up 40.87% from a year prior.
  • Other Non-Current Assets hit $6.7 million in Q4 2025 for Cytek Biosciences, up from $4.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.7 million in Q4 2025 to a low of $30000.0 in Q2 2024.
  • Median Other Non-Current Assets over the past 5 years was $2.9 million (2023), compared with a mean of $2.8 million.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 99.02% in 2024 and later surged 14283.87% in 2025.
  • Cytek Biosciences' Other Non-Current Assets stood at $1.3 million in 2021, then soared by 123.52% to $2.9 million in 2022, then tumbled by 88.58% to $331000.0 in 2023, then skyrocketed by 1337.76% to $4.8 million in 2024, then surged by 40.87% to $6.7 million in 2025.
  • The last three reported values for Other Non-Current Assets were $6.7 million (Q4 2025), $4.5 million (Q3 2025), and $4.6 million (Q1 2025) per Business Quant data.